Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016

  • ID: 3766788
  • Drug Pipelines
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • OPKO Health, Inc.
  • PTC Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Zogenix, Inc.
  • MORE
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016

Summary

The report ‘Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016’, provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
- The report reviews pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics and enlists all their major and minor projects
- The report assesses Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • OPKO Health, Inc.
  • PTC Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Zogenix, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview

Therapeutics Development

Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development

Biscayne Pharmaceuticals, Inc.

GW Pharmaceuticals Plc

INSYS Therapeutics, Inc.

OPKO Health, Inc.

PTC Therapeutics, Inc.

Sage Therapeutics, Inc.

Xenon Pharmaceuticals Inc.

Zogenix, Inc.

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ataluren - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BIS-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CUR-1916 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fenfluramine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Dravet Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAGE-217 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Recent Pipeline Updates

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones

Featured News & Press Releases

May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome

Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress

Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol)

Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals

Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome

Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome

Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug

Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy

Dec 07, 2015: Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics - Recent Pipeline Updates, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Biscayne Pharmaceuticals, Inc.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
OPKO Health, Inc.
PTC Therapeutics, Inc.
Sage Therapeutics, Inc.
Xenon Pharmaceuticals Inc.
Zogenix, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll